pravastatin

(redirected from Mevalotin)
Also found in: Thesaurus, Medical.
Related to Mevalotin: pravastatin, Ezetrol

prav·a·stat·in

 (prăv′ə-stăt′n)
n.
A statin drug, C 23H36O7, that blocks the body's synthesis of cholesterol and is used in its sodium form to lower cholesterol (especially LDL) levels and to reduce the risk of heart attack and stroke in individuals with elevated risk.

[pra-, of unknown origin + -vastatin, statin suffix (from mevastatin, a statin : meva(lonic acid), precursor in the biosynthesis of cholesterol from val(eric acid) + -stat + -in).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.pravastatin - an oral drug (trade name Pravachol) administered to reduce blood cholesterol levels; recommended after nonfatal heart attacks
lipid-lowering medication, lipid-lowering medicine, statin, statin drug - a medicine that lowers blood cholesterol levels by inhibiting HMG-CoA reductase
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
Translations

pravastatin

n pravastatina
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Although sales of Olmetec grew substantially in Europe and the United States, they failed to offset a fall in sales of mainstay lipid-lowering drug Mevalotin and effects of the withdrawal from some of its medical goods operations, Sankyo said.
Sankyo said a sharp rise in bulk exports of its mainstay Mevalotin drug for hyperlipidemia to the United States helped offset a sales decline in the domestic market caused by increased competition and the launch of a generic drug.
Sankyo said bulk shipments of its blockbuster drug, Mevalotin hyperlipidemia agent, surged during the six months to help offset a sales slowdown in the domestic market where the drug's patent had expired and generic competition is heating up.